West Haven, Connecticut 06516


Purpose:

The overall purpose of this study is to examine the effect of N-acetylcysteine (NAC) on the acute effects of Delta-9-tetrahydrocannabinol (THC). This will be tested by pretreating healthy individuals with NAC and then assessing their responses to THC.


Criteria:

Inclusion Criteria: - Exposed to Cannabis at least once in lifetime Exclusion Criteria: - Cannabis Naive - Individuals with a documented allergy to N-acetylcysteine


NCT ID:

NCT02335060


Primary Contact:

Principal Investigator
Mohini Ranganathan, MD
Yale University Medical School

Esra Sefik, BA
Phone: 203-932-5711 ext. 2557
Email: esra.sefik@yale.edu


Backup Contact:

Email: christina.luddy@yale.edu
Christina Luddy, BS
Phone: 203-932-5711 ext. 4549


Location Contact:

West Haven, Connecticut 06516
United States

Christina Luddy, BS
Phone: 203-932-5711
Email: christina.luddy@yale.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 22, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.